Despite the availability of different treatment options and strategies for RA patients, the response to treatment with DMARDs is still suboptimal. Strategies to optimize the pharmacological therapy of RA are therefore warranted. Two possible strategies to improve treatment outcome in RA were therefore studied in this thesis: improving adherence to DMARD-therapy and therapeutic drug monitoring of one of the biological agents: infliximab. First, improving adherence to traditional DMARDs could not only increase the effectiveness of a drug, but it could also indirectly delay the necessity of applying (more expensive) biological therapy as traditional DMARDs are more efficacious due to better adherence. In this thesis we show that, depending on ...
Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear and con...
Purpose of reviewTo give an overview of recently published articles covering therapeutic drug monito...
Juha Laine,1 T Sakari Jokiranta,2,3 Kari K Eklund,4,5 Merja Väkeväinen,1 Kari Puolakka6 1P...
Contains fulltext : 81554.pdf (publisher's version ) (Open Access)Despite the avai...
Background: Therapeutic Drug Monitoring is part of standard patient care and utilizes pharmacokineti...
International audienceThe treatment of rheumatoid arthritis (RA) has largely improved in the biophar...
Clinical response in patients with rheumatoid arthritis (RA) treated with biologic agents can be inf...
The advent of biological therapies has been a major therapeutic advance in rheumatology. Many patien...
INTRODUCTION: Biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) have improved the treatmen...
Objective. Infliximab, an anti-tumor necrosis factor alpha (anti-TNF alpha) antibody, is effective i...
OBJECTIVE and DESIGN Adalimumab (ADA) is effective in the treatment of rheumatoid arthritis IRA), an...
Conventional DMARDs such as MTX are the mainstay of treatment for patients with RA. However, failure...
Aim: It is well established that tumor necrosis factor (TNF) inhibitors help control disease activit...
In the treatment of rheumatoid arthritis (RA), optimal individual dosing of biologic disease modifyi...
Abstract Background A substantial proportion of rheumatoid arthritis (RA) patients discontinues trea...
Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear and con...
Purpose of reviewTo give an overview of recently published articles covering therapeutic drug monito...
Juha Laine,1 T Sakari Jokiranta,2,3 Kari K Eklund,4,5 Merja Väkeväinen,1 Kari Puolakka6 1P...
Contains fulltext : 81554.pdf (publisher's version ) (Open Access)Despite the avai...
Background: Therapeutic Drug Monitoring is part of standard patient care and utilizes pharmacokineti...
International audienceThe treatment of rheumatoid arthritis (RA) has largely improved in the biophar...
Clinical response in patients with rheumatoid arthritis (RA) treated with biologic agents can be inf...
The advent of biological therapies has been a major therapeutic advance in rheumatology. Many patien...
INTRODUCTION: Biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) have improved the treatmen...
Objective. Infliximab, an anti-tumor necrosis factor alpha (anti-TNF alpha) antibody, is effective i...
OBJECTIVE and DESIGN Adalimumab (ADA) is effective in the treatment of rheumatoid arthritis IRA), an...
Conventional DMARDs such as MTX are the mainstay of treatment for patients with RA. However, failure...
Aim: It is well established that tumor necrosis factor (TNF) inhibitors help control disease activit...
In the treatment of rheumatoid arthritis (RA), optimal individual dosing of biologic disease modifyi...
Abstract Background A substantial proportion of rheumatoid arthritis (RA) patients discontinues trea...
Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear and con...
Purpose of reviewTo give an overview of recently published articles covering therapeutic drug monito...
Juha Laine,1 T Sakari Jokiranta,2,3 Kari K Eklund,4,5 Merja Väkeväinen,1 Kari Puolakka6 1P...